Why the study?
The study investigated the effects of cardiomyopathic mutations E56G, M149V, and E177G in the MYL3 gene encoding ELCv on the functional properties of cardiac myosin and its isolated head.
Cardiomyopathic mutations in the MYL3 gene (E56G, M149V, E177G) associated with hypertrophic cardiomyopathy alter actin-myosin interaction through distinct mechanisms, primarily by increasing Ca2+-sensitivity.
These in vitro myosin effects remain hypothesis-generating; leaves open clinical relevance for MYL3 cardiomyopathy.
The effects of cardiomyopathic mutations E56G, M149V, and E177G in the MYL3 gene encoding essential light chain of human ventricular myosin (ELCv), on the functional properties of cardiac myosin and its isolated head (myosin subfragment 1, S1) were investigated. Only the M149V mutation upregulated the actin-activated ATPase activity of S1. All mutations significantly increased the Ca2+-sensitivity of the sliding velocity of thin filaments on the surface with immobilized myosin in the in vitro motility assay, while mutations E56G and M149V (but not E177G) reduced the sliding velocity of regulated thin filaments and F-actin filaments almost twice. Therefore, despite the fact that all studied mutations in ELCv are involved in the development of hypertrophic cardiomyopathy, the mechanisms of their influence on the actin-myosin interaction are different.
No takes yet. Share an insight, caveat, or question.
Yampolskaya et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: